



Correction to: Multi-center, randomized, double-blind, placebocontrolled study of quetiapine extended-release formulation in Japanese patients with bipolar depression

Mitsukuni Murasaki¹ · Tsukasa Koyama² · Shigenobu Kanba³ · Masahiro Takeuchi⁴ · Yuriko Shimizu⁵ · Eri Arita⁶ · Kentaro Kuroishi⁷ · Masahiro Takeuchi⁸ · Shinya Kamei⁵

Published online: 17 September 2018

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Correction to: Psychopharmacology

<https://doi.org/10.1007/s00213-018-4977-6>

The original version of this article contained a mistake in Table 5. Correct version is presented here.

The online version of the original article can be found at <https://doi.org/10.1007/s00213-018-4977-6>

✉ Shinya Kamei
shinya.kamei@astellas.com

Mitsukuni Murasaki
murasaki@i-cnsp.com

Tsukasa Koyama
koyama@ohyachi-hp.or.jp

Shigenobu Kanba
skanba@npsych.med.kyushu-u.ac.jp

Masahiro Takeuchi
takeuchim@pharm.kitasato-u.ac.jp

Yuriko Shimizu
yuriko.shimizu@astellas.com

Eri Arita
eri.arita@astellas.com

Kentaro Kuroishi
kentarou.kuroishi@astellas.com

Masahiro Takeuchi
masahiro-takeuchi@astellas.com

- ¹ Institute of CNS Pharmacology, 3-14-20 Sagami-cho, Minami-ku, Sagami-hara, Kanagawa 252-0303, Japan
- ² Ohyachi Hospital, Clinical Research Center, 5-7-10 Ohyachi-higashi, Atsubetsu-ku, Sapporo, Hokkaido 004-0041, Japan
- ³ Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
- ⁴ Department of Clinical Medicine, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
- ⁵ Japan/Asia Clinical Development 2, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan
- ⁶ Global Clinical Science, Astellas Pharma Europe B.V, Sylviusweg 62, PO Box 344, 2300 AH Leiden, The Netherlands
- ⁷ Japan-Asia Data Science, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan
- ⁸ Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL 60062, USA

Table 5 Changes in clinical laboratory evaluations

	Baseline				End of treatment				Change from baseline									
	Placebo group		Quetiapine XR 300 mg group		Placebo group		Quetiapine XR 300 mg group		Placebo group		Quetiapine XR 300 mg group		Quetiapine XR 150 mg group					
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD				
Body weight (kg)	62.65	13.10	63.15	13.71	64.09	13.06	62.32	13.37	64.16	13.92	64.33	12.87	-0.54	1.96	0.92	2.35	0.45	2.27
Blood glucose (mg/dL)	97.9	15.8	98.5	14.2	96.8	13.9	98.4	16.3	101.3	17.1	97.1	12.3	0.5	19.2	3.1	18.1	0.3	15.8
HbA 1c (%)	5.01	0.28	5.05	0.27	5.07	0.28	5.03	0.29	5.06	0.31	5.06	0.32	0.01	0.15	0.01	0.17	-0.01	0.24
Total cholesterol (mg/dL)	195.1	39.9	191.0	35.6	192.7	40.8	191.2	33.4	195.5	37.5	193.8	36.1	-4.1	23.3	4.9	26.0	1.1	28.2
HDL-C (mg/dL)	58.1	14.4	56.5	16.7	55.3	13.1	57.8	14.1	55.7	16.3	54.4	13.5	-0.2	8.2	-0.7	8.0	-0.9	9.0
LDL-C (mg/dL)	117.2	37.4	115.4	32.0	116.9	36.3	115.3	31.3	118.4	32.3	119.1	31.2	-2.3	21.5	3.2	18.7	2.2	22.8
Triglycerides (mg/dL)	136.4	109.8	128.2	80.1	126.8	92.8	121.6	86.2	147.0	112.4	139.3	106.6	-15.1	87.8	18.9	91.3	12.5	62.5
Prolactin (ng/mL)	11.983	15.409	10.529	6.779	9.044	4.491	12.433	20.655	12.375	19.305	10.300	5.286	0.375	23.310	1.877	19.479	1.256	4.504

HbA1c, hemoglobin A1c; *HDL-C*, high-density lipoprotein-cholesterol; *LDL-C*, low-density lipoprotein-cholesterol